Blueprint
Tenax Therapeutics Provides Regulatory Update on
Levosimendan
Morrisville, NC, July 28, 2017 – Tenax Therapeutics, Inc. (NASDAQ: TENX), a
specialty pharmaceutical company focused on identifying, developing
and commercializing products for the critical care market, today
provides a regulatory update following discussions with the U.S.
Food and Drug Administration (FDA) and Health Canada regarding
a regulatory path forward for levosimendan.
In May 2017, the Company participated in a pre-NDA meeting with the
FDA to discuss the possibility of submitting an NDA for
levosimendan in two indications: treatment of patients undergoing
coronary artery bypass grafting (CABG) to reduce the risk of low
cardiac output syndrome (LCOS) and treatment of patients with acute
decompensated heart failure (ADHF) for improvement in symptoms.
After a review of further analyses, the FDA has requested an
additional clinical trial. Given the size and scope of such a
trial, the Company is reviewing clinical, regulatory and financial
options with regard to the levosimendan program in the U.S. and
Canada.
The Company's Board of Directors is continuing its review of
strategic alternatives with the assistance of their financial
advisors at Ladenburg Thalmann & Co. Inc. Strategic
alternatives under review include, but are not limited to a merger,
a business combination, a strategic investment into the Company, or
a purchase, license or other acquisition of assets. This process
may not result in any transaction and the Company does not intend
to disclose additional details unless and until it has entered into
a specific transaction.
About Levosimendan
Levosimendan is a calcium sensitizer that works through a unique
triple mechanism of action. It initially was developed for
intravenous use in hospitalized patients with acutely decompensated
heart failure. It was discovered and developed by Orion Pharma,
Orion Corporation of Espoo Finland, and is currently approved in
over 60 countries for this indication and not available in the
United States. Tenax Therapeutics acquired the North American
rights to develop and commercialize levosimendan from Phyxius
Pharma.
About Tenax Therapeutics
Tenax Therapeutics, Inc., is a specialty pharmaceutical company
focused on identifying, developing and commercializing products for
the critical care market. For more information, visit
www.tenaxthera.com.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by
the company that involve risks and uncertainties and reflect the
company’s judgment as of the date of this release. The
forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to matters beyond the
company's control that could lead to delays in the clinical study,
delays in new product introductions and customer acceptance of
these new products, and other risks and uncertainties as described
in the company’s filings with the Securities and Exchange
Commission, including in its transition report on Form 10-K filed
on March 16, 2017, its quarterly report on Form 10-Q filed on May
10, 2017 as well as its other filings with the SEC. The company
disclaims any intent or obligation to update these forward-looking
statements beyond the date of this release. Statements in this
press release regarding management’s future expectations,
beliefs, goals, plans or prospects constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995.
Investor Contact
Will
O‘Connor
Stern
Investor Relations, Inc.
will@sternir.com
212-362-1200